Quick Takeaways
- Baselake Partners, LP filed SCHEDULE 13G for Neuphoria Therapeutics Inc. Common Stock, $0.00001 par value per share (NEUP).
- Disclosed ownership: 9.4%.
- Date of event: 27 Oct 2025.
Baselake Partners, LP - 27 Oct 2025 SCHEDULE 13G Report for Neuphoria Therapeutics Inc. Common Stock, $0.00001 par value per share (NEUP)
- Filing Manager
- Baselake Partners, LP
- Reporting Manager
- Baselake Partners, LP
- Symbol
- NEUP
- Shares outstanding
- 2,364,064 shares
- Disclosed Ownership
- 222,222 shares
- Ownership
- 9.4%
- Form type
- SCHEDULE 13G
- Filing time
- 31 Oct 2025, 16:31:10 UTC
- Date of event
- 27 Oct 2025
- Next filing
- 06 Feb 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Baselake Partners, LP disclosed 9.4% ownership in Neuphoria Therapeutics Inc. Common Stock, $0.00001 par value per share (NEUP) on 27 Oct 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Oct 2025, 16:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Baselake Partners, LP | 9.4% | 222,222 | 0 | 222,222 | /s/ David Paolella | David Paolella, Managing Member of Baselake Management, LLC, its investment manager | |
| Baselake Management, LLC | 9.4% | 222,222 | 0 | 222,222 | /s/ David Paolella | David Paolella, Managing Member | |
| David Paolella | 9.4% | 222,222 | 0 | 222,222 | /s/ David Paolella | Individually |